Zydus Lifesciences Q2 FY27: revenue up 29.2% to ₹7,910 Cr, net profit down 25.1% to ₹928 Cr
Results · Finvezto · 4 Nov 2026 · Zydus Lifesciences (ZYDUSLIFE)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 7,910 | -1.3% | +29.2% |
| Operating profit | 1,895 | -1.8% | -6.0% |
| Net profit | 928 | -6.3% | -25.1% |
| Operating margin | 24.0% | -0.1 pp | -9.0 pp |
| Net margin | 11.7% | -0.6 pp | -8.5 pp |
Key points
- Zydus Lifesciences reported consolidated revenue from operations of Rs 7,909.6 crore for Q2 FY27, up 29% year-on-year, while EBITDA fell 6% to Rs 1,894.5 crore and net profit dropped 27% to Rs 925.5 crore. NSE filing
- Research and development investments stood at Rs 657.3 crore, representing 8.3% of revenues, while organic capital expenditure for the quarter reached Rs 465.5 crore. NSE filing
- Zydus Lifesciences registered consolidated revenues of ₹79.1 billion in Q2 FY27, up 29% year-on-year, with net profit reaching ₹9.3 billion. Earnings call
- Operating EBITDA margin stood at 24%, or 150 basis points higher when adjusted for Saroglitazar US launch-related investments. Earnings call
What to watch
- Management on ebitda margin: Despite these investments, our operating profitability remained robust and we are on track to deliver a 24% plus EBITDA margin in line with our FY27 expectations.
- Management on full year ebitda margin: Yes, we maintain that guidance of 24% EBITDA margin for the full year.
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 26.5%, 33.7%, 24.1%, 24.0%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 1,023, 1,341, 990, 928.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.